INBX (Inhibrx Biosciences) EV-to-EBIT : 0.02 (As of May. 19, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Inhibrx Biosciences's Enterprise Value is $33.87 Mil. Inhibrx Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $1,731.02 Mil. Therefore, Inhibrx Biosciences's EV-to-EBIT for today is 0.02.

The historical rank and industry rank for Inhibrx Biosciences's EV-to-EBIT or its related term are showing as below:

INBX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.11 Med: 0.02 Max: 0.06
Current: 0.02

During the past 3 years, the highest EV-to-EBIT of Inhibrx Biosciences was 0.06. The lowest was -1.11. And the median was 0.02.

INBX's EV-to-EBIT is ranked better than
97.88% of 471 companies
in the Biotechnology industry
Industry Median: 7.79 vs INBX: 0.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Inhibrx Biosciences's Enterprise Value for the quarter that ended in Mar. 2025 was $0.00 Mil. Inhibrx Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $1,731.02 Mil. Inhibrx Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was %.

Inhibrx Biosciences EV-to-EBIT Historical Data

The historical data trend for Inhibrx Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences EV-to-EBIT Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

EV-to-EBIT

0.05

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial					-	-0.01	0.02	0.05	-

Competitive Comparison of Inhibrx Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Inhibrx Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Inhibrx Biosciences EV-to-EBIT Calculation

Inhibrx Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	33.868	/	1731.023
	=	0.02

Inhibrx Biosciences's current Enterprise Value is $33.87 Mil.
Inhibrx Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,731.02 Mil.

Inhibrx Biosciences (NAS:INBX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Inhibrx Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	1731.023	/	0
	=	%

Inhibrx Biosciences's Enterprise Value for the quarter that ended in Mar. 2025 was $0.00 Mil.
Inhibrx Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,731.02 Mil.

Inhibrx Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.